MA
REGN icon

MCF Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

MCF Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.5K Sell
42
-3
-7% -$2.3K ﹤0.01% 702
2025
Q4 		$34.7K Buy
45
+15
+50% +$10.2K ﹤0.01% 575
2025
Q3 		$16.9K Hold
30
– – ﹤0.01% 608
2025
Q2 		$15.8K Hold
30
– – ﹤0.01% 589
2025
Q1 		$19K Sell
30
-6
-17% -$4.13K ﹤0.01% 561
2024
Q4 		$25.6K Hold
36
– – ﹤0.01% 509
2024
Q3 		$37.8K Sell
36
-5
-12% -$5.56K ﹤0.01% 437
2024
Q2 		$43.1K Buy
41
+6
+17% +$5.82K ﹤0.01% 410
2024
Q1 		$33.7K Sell
35
-1
-3% -$951 ﹤0.01% 443
2023
Q4 		$31.6K Buy
36
+12
+50% +$9.88K ﹤0.01% 440
2023
Q3 		$19.8K Hold
24
– – ﹤0.01% 488
2023
Q2 		$17.2K Hold
24
– – ﹤0.01% 497
2023
Q1 		$19.7K Buy
24
+20
+500% +$15.1K ﹤0.01% 475
2022
Q4 		$2.89K Hold
4
– – ﹤0.01% 642
2022
Q3 		$3K Hold
4
– – ﹤0.01% 653
2022
Q2 		$2K Hold
4
– – ﹤0.01% 640
2022
Q1 		$3K Buy
+4
New +$2.53K ﹤0.01% 613
2021
Q4 		– Sell
-4
Closed -$2K – 529
2021
Q3 		$2K Buy
+4
New +$2.48K ﹤0.01% 630

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MCF Advisors's REGN Position: Q1 2026 in Review

MCF Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 6.7% in Q1 2026, selling an estimated $2.3K and leaving 42 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #702.

MCF Advisors first reported a position in REGN in Q3 2021 and has held it in 18 quarters since. The position peaked at $43.1K in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • MCF Advisors held 42 shares of Regeneron Pharmaceuticals worth $32.5K as of Q1 2026.
  • MCF Advisors sold 3 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.3K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #702 holding.
  • MCF Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • MCF Advisors's Regeneron Pharmaceuticals position peaked at $43.1K in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.